Linda Palczuk Biography and Net Worth

Director of Avadel Pharmaceuticals

Linda S. Palczuk has been a member of the Avadel Board of Directors since July 2018. Since September 2019, Linda has been the Chief Operating Officer and a Director of Envara Health, Inc., a medical nutrition technology company. Prior to Envara Health, Linda was the Chief Operating Officer of Verrica Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on medical dermatology products, and before that, she was President and Chief Executive Officer at Osiris Therapeutics, Inc., a regenerative medicines biotechnology company. Linda also had an extensive and successful 30-year career with AstraZeneca Pharmaceuticals and its legacy companies, serving in senior-level commercial and general management roles, including Vice President, Established Brands; Vice President, Global Commercial Excellence; Vice President, Sales & Marketing; and Vice President, Sales. Linda received a BA in biology from Franklin and Marshall College and an MBA degree from the Alfred Lerner College of Business and Economics at the University of Delaware.

What is Linda Palczuk's net worth?: The estimated net worth of Linda Palczuk is at least $642,673.50 as of January 21st, 2025. Ms. Palczuk owns 67,900 shares of Avadel Pharmaceuticals stock worth more than $642,674 as of May 7th. This net worth estimate does not reflect any other investments that Ms. Palczuk may own. Learn More about Linda Palczuk's net worth.
How do I contact Linda Palczuk?: The corporate mailing address for Ms. Palczuk and other Avadel Pharmaceuticals executives is 10 EARLSFORT TERRACE, DUBLIN L2, D02. Avadel Pharmaceuticals can also be reached via phone at (531) 901-5201 and via email at investors@avadel.com. Learn More on Linda Palczuk's contact information.
Has Linda Palczuk been buying or selling shares of Avadel Pharmaceuticals?: Linda Palczuk has not been actively trading shares of Avadel Pharmaceuticals in the last ninety days. Most recently, on Tuesday, January 21st, Linda Palczuk bought 5,000 shares of Avadel Pharmaceuticals stock. The stock was acquired at an average cost of $7.93 per share, with a total value of $39,650.00. Following the completion of the transaction, the director now directly owns 67,900 shares of the company's stock, valued at $538,447. Learn More on Linda Palczuk's trading history.
Who are Avadel Pharmaceuticals' active insiders?: Avadel Pharmaceuticals' insider roster includes Gregory Divis (CEO), Geoffrey Glass (Director), Geoffrey Glass (Director), Thomas McHugh (CFO), Linda Palczuk (Director), and Peter Thornton (Director). Learn More on Avadel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Avadel Pharmaceuticals?: During the last twelve months, Avadel Pharmaceuticals insiders bought shares 8 times. They purchased a total of 55,579 shares worth more than $526,363.04. The most recent insider tranaction occured on January, 21st when Director Linda Palczuk bought 5,000 shares worth more than $39,650.00. Insiders at Avadel Pharmaceuticals own 4.8% of the company. Learn More about insider trades at Avadel Pharmaceuticals.
Information on this page was last updated on 1/21/2025.

Linda Palczuk Insider Trading History at Avadel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/21/2025	Buy	5,000	$7.93	$39,650.00	67,900
12/6/2024	Buy	3,000	$10.19	$30,570.00	66,400
5/9/2023	Buy	2,500	$14.76	$36,900.00	52,400
12/23/2022	Buy	2,000	$7.20	$14,400.00	49,900
5/27/2022	Buy	10,000	$1.60	$16,000.00	47,900
8/14/2020	Buy	2,500	$7.94	$19,850.00

Linda Palczuk Buying and Selling Activity at Avadel Pharmaceuticals

Avadel Pharmaceuticals Company Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Today's Range

Now: $9.47

$8.84

$9.98

50 Day Range

MA: $8.04

$6.59

$9.47

2 Week Range

Now: $9.47

$6.38

$17.85

Volume

2,811,718 shs

Average Volume

1,241,343 shs

Market Capitalization

$914.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4